The Motley Fool

Should you invest in banking or pharma stocks for retirement right now?

Image source: Getty Images.

Should you invest in big banking stocks or big pharmaceutical stocks right now? Both seem to be presenting an opportunity, but they are very different beasts.

Big pharmaceuticals such as GlaxoSmithKline, AstraZeneca and Shire earn the label ‘defensive’ because their underlying businesses tend to be good at generating incoming cash flow whatever the general economic weather. Selling medicines is a classic consumer goods set-up. Customers return time and again for their drugs, rarely missing a purchase just because economic times might be tough, which is great for investor dividends.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

Big banking firms such as HSBC Holdings, Lloyds Banking Group and Barclays fall into the category of ‘cyclicals’ because their underlying businesses tend to thrive or shrivel depending on the health of wider economic cycles. Instead of the constant cash flow we see with defensives, cyclicals often suffer from plunging cash flows and falling share prices when economic times are hard, which is bad for investor dividends.

An emerging opportunity and a constant threat

Defensives are becoming cheaper because their share prices have been falling for the past year or so, mostly because valuations had risen too high. These also tend to fluctuate in a cycle of their own. When economic times are uncertain — such as over the past 10 years since the credit crunch — investors find the stability of defensives attractive and they buy their shares, driving share prices up. On top of that, interest rates have been low for so long that we’ve seen the so-called bond-proxy trade go something like this: “I can’t get a decent rate of interest on bonds or from bank accounts but look at those juicy dividend yields from defensive shares over there!”

Valuations of defensive firms appear to be cycling down right now. I think we’re seeing an investor rotation out of pricey defensives, such as big pharmaceutical stocks, and into cheap-looking cyclicals, such as big banking stocks. The general economic outlook is quite good, and the valuations of cyclical firms have looked low for some time. But I think there is a good reason for the market assigning a low valuation to the big banks and other cyclical firms. The market knows their profits tend to cycle up and down, and profits have been high for the banks and other cyclicals for some time. So, I think the market is keeping a lid on big bank valuations right now in anticipation of profits cycling down again at some point.

Yet economies are doing well and interest rates are on the rise. One argument goes that banks thrive in a higher-interest-rate environment. Maybe so, but I’m not expecting interest rates to shoot the lights out in the current macro-cycle, and I’m not expecting the market to raise the valuations of banks to growth-style ratings. I am, however, expecting a cyclical plunge in banks share prices, profits and dividends at some point. Such an event may be years away, but it’s still a threat. To me, the compelling retirement investing opportunity hidden in the banks-versus-pharma stocks debate is with the pharmas, and I’m ready to pounce.

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!

Kevin Godbold has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca, Barclays, HSBC Holdings, Lloyds Banking Group, and Shire. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

The renowned analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply enter your email address below to discover how you can take advantage of this.

I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement.